NCT01860586View on ClinicalTrials.gov

Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Retinal DetachmentVitreoretinopathy Proliferative
Interventions
DRUG

Bevacizumab

Bevacizumab (1.25mg/0.05mL) will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.

Trial Locations (1)

19107

Mid Atlantic Retina- Wills Eye Institute, Philadelphia

All Listed Sponsors
lead

Wills Eye

OTHER

NCT01860586 - Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment. | Biotech Hunter | Biotech Hunter